Ligand-Based Targeted Delivery: Definition, Mechanisms, and Applications

Targeted delivery mediated by ligands is emerging as a major approach to modern drug design and discovery. In this approach, rather than passively distributing a therapeutic drug to cells throughout the body, one can now direct therapeutic cargoes to a diseased cell using an exquisite level of selectivity. Ligands that are commonly used as targeting agents include antibodies, peptides, or small molecules, and these are capable of binding to specific receptors that are present on target cells. This targeting strategy not only improves treatment efficacy but also minimizes side effects associated with off-target toxicity. As a trusted partner in advanced delivery solutions, Creative Biolabs offers comprehensive expertise in ligand design, carrier engineering, and conjugation technologies to support research from concept to preclinical development.

Introduction: What Is Ligand-Based Targeted Delivery?

Most conventional drug delivery systems, including those for chemotherapeutic drugs targeting tumors or systemically administered drugs for colonic diseases, have one major limitation: the nonspecific distribution of drugs in the body. This limitation not only damages normal cells but also does not allow concentrating the drugs in the lesion site, which results in severe toxic side effects as well as lower efficacy. To address this, ligand-based targeted delivery has emerged as a precision strategy redefining drug delivery. By definition, ligand-based targeted delivery (currently also called active targeting) leverages specific ligands, molecules with high affinity for receptors/biomarkers overexpressed on target cells (e.g., tumor cells, inflamed intestinal cells), to guide therapeutic agents (small-molecule drugs, nanoparticles, etc.) to intended action sites. The ligands include small molecules (vitamin ligands), polysaccharides (such as hyaluronic acid), peptides (such as RGD), antibodies, and aptamers. As "homing devices", they target and bind to specific cognate receptors expressed on target cells to induce receptor-mediated endocytosis, active transport, or enhanced penetration mechanisms for drug internalization. For example, folic acid can bind to folate receptors overexpressed on breast/ovarian cancer cells, thus enabling the selective delivery of folate-conjugated drugs.

Unlike passive targeting (e.g., the EPR effect, which relies on leaky tumor vasculature), which is heterogeneous and inefficient (with only ~0.7% of nanocarriers reaching tumors), ligand-based delivery ensures precision even in lesions with weak EPR effects through molecular recognition. Its importance is reflected in two key aspects: on one hand, it enhances therapeutic efficacy. Antibody-drug conjugates (ADCs) enable higher intracellular concentrations of the drug, thereby enhancing its efficacy. On the other hand, it lessens systemic toxicity. For instance, folate-conjugated liposomal doxorubicin is proven to reduce cardiotoxicity when compared with free doxorubicin. This dual advantage makes ligand-based targeted delivery indispensable for advancing the development of therapies targeting tumors, colonic disorders, and other related conditions.

As a leading CRO partner, Creative Biolabs-Targeted Delivery supports end-to-end ligand-targeted programs, from ligand screening and conjugation chemistry to in vitro/in vivo validation.

Why Ligands Matter in Targeted Delivery?

Ligands are pivotal in targeted delivery, addressing core limitations of conventional systems by enabling five key benefits (Table 1). First, specific tissue targeting allows ligands to precisely guide payloads to disease sites. For example, folate-drug conjugates can accumulate in folate receptor-positive tumors to avoid healthy tissue damage. Second, they boost cellular uptake: transferrin-modified nanoparticles harness transferrin receptors to cross the blood-brain barrier (BBB), thus enhancing intracellular drug exposure. Third, ligands support controlled release: pH-cleavable linkers can be incorporated in ligand-drug conjugates to ensure drug release only in the acidic tumor microenvironment, thereby reducing off-target release. Fourth, they fit broader modalities. They can deliver diverse molecules, such as small molecules, biologics, or nucleic acids, for various applications. Finally, translational flexibility enables ligand choice to align with clinical needs. For example, antibody fragments can reduce carrier size to improve tumor penetration. These benefits make ligands indispensable for precision therapy.

Table 1 Characteristics of Ligands in Targeted Delivery.

Practical next step: shortlist ligand-target pairs that match your biology, then pick a compatible carrier + linker from our Module Delivery Systems to accelerate feasibility.

How Ligand-Based Targeting Works?

At its core, ligand-targeted delivery follows a simple, precision-driven logic, with four key steps grounded in molecular recognition and cellular biology (Figure 1).

Target identification

First, target identification focuses on receptors/biomarkers overexpressed on pathological cells. For example, folate receptors (FR) are abundant on ovarian, breast, and lung cancer cells, CD44 receptors are overexpressed on colorectal cancer cells, and transferrin receptors (TfR) are enriched on glioma cells. These targets are rarely present on normal cells, therefore laying the foundation for specificity.

Ligand selection and conjugation

Second, ligand selection and conjugation involve pairing the target with a high-affinity ligand. Common ligands include folic acid (for FR), hyaluronic acid (for CD44), transferrin (for TfR), peptides such as RGD (for integrins), antibodies such as trastuzumab (for HER2), and aptamers. These ligands are covalently or non-covalently attached to a delivery vehicle.

Vehicle integration

Third, vehicle integration combines the ligand with a carrier (liposomes, polymeric nanoparticles, micelles, or exosomes) loaded with drugs, siRNA, or photosensitizers. For instance, oxaliplatin can be delivered to colorectal cancer cells by folate-conjugated PLGA nanoparticles.

Binding and Internalization

Finally, binding and internalization occur when the ligand binds its target receptor, triggering receptor-mediated endocytosis (clathrin- or caveolae-mediated endocytosis), which pulls the vehicle into the cell. Inside, therapeutic payloads are released (e.g., via pH-sensitive linkers in acidic tumor microenvironments) to target intracellular sites. Carriers and linkers are designed to escape endosomes (e.g., proton sponge effect) or release payload at endosomal pH.

• Design insight: select a receptor with robust internalization and consistent expression across your patient segment. Then tune ligand density and linker sensitivity to match the receptor's trafficking.

This mechanism ensures payload accumulation at diseased sites, thereby boosting efficacy (e.g., antibody-drug conjugates achieving higher intracellular drug levels) and reducing systemic toxicity (e.g., folate-liposomal doxorubicin lowering cardiotoxicity).

Why it matters: This mechanism ensures payload accumulation at diseased sites, thereby boosting efficacy (e.g., antibody-drug conjugates achieving higher intracellular drug levels) and reducing systemic toxicity (e.g., folate-liposomal doxorubicin lowering cardiotoxicity).

Fig.1 Folate-mediated targeted drug delivery.³

Types of Ligands & Where They Shine

There are five types of ligands applied in targeted delivery: antibodies and antibody fragments, peptides, aptamers, small molecules, and carbohydrates. This section translates molecular choices into concrete applications grounded in research to help scientists evaluate practical use cases (Table 2).

Antibodies and Antibody Fragments

What they are:

Whole IgG antibodies (e.g., trastuzumab) or engineered fragments such as single-chain variable fragments (scFv), antigen-binding fragments (Fab), and variable heavy domains (VHH).

Why they work:

• Exceptional affinity and specificity for validated antigens (e.g., HER2, EGFR);
• Well-established clinical precedent;
• Flexible engineering for payload attachment.

Key applications:

• Tumor targeting: HER2-directed antibodies guide liposomes/nanoparticles to breast cancer cells; EGFR antibodies can enhance photodynamic therapy (PDT) in head-and-neck tumors.
• Immune cell retargeting: CD19/CD20 antibodies can bind specifically to CD19/CD20 receptors that are overexpressed on B-cell malignancies (e.g., non-Hodgkin lymphoma, chronic lymphocytic leukemia) while sparing normal B cells, thereby enabling selective delivery of therapeutic payloads (e.g., cytotoxic drugs, immunomodulators) to diseased B cells.

Where to use:

When targets are well-characterized (e.g., FR-ɑ in ovarian cancer) and internalization is required.

Pro tip:

Use VHH to reduce size for improved tumor penetration. For example, the variable heavy domains of EGFR can improve tumor penetration in dense glioblastoma microenvironments vs. full IgG.

Peptides

What they are:

Short amino-acid sequences (5-50 residues) that bind receptors/transporters.

Why they work:

• Small (enhances penetration);
• Customizable;
• Low-cost to synthesize;
• Compatible with multivalent display (e.g., RGD on nanoparticles).

Key applications

• RGD/iRGD: Binds integrins (αvβ3) on tumor vasculature for tumor homing and deep penetration.
• Angiopep-2: Engages LRP1 to cross the blood-brain barrier (BBB) for glioma drug delivery.
• TAT (a cell-penetrating peptide, CPP): Facilitates cellular uptake of macromolecules and nanoparticles.

Where to use:

When BBB crossing, cost efficiency, or penetration in dense tumors (e.g., pancreatic cancer) is critical.

Aptamers

What they are:

Short, structured ssDNA/RNA oligonucleotides that fold to bind targets with antibody-like specificity.

Why they work:

• Chemically synthesized (low immunogenicity);
• Tunable via modifications (2'-fluoro, PEGylation) to extend circulation;
• SELEX-based screening for new targets.

Key applications

• Nucleic acid delivery: Guides siRNA to nucleolin-overexpressing breast cancer cells.
• Imaging: Binds VEGF for tumor imaging in colorectal cancer.

Where to use:

When fully synthetic ligands, clear IP, or fine control over affinity (e.g., optimizing for low-dose therapy) is needed.

Small Molecules (such as Vitamin Ligands)

What they are:

Compact, low-molecular-weight ligands with known receptors and simple conjugation.

Why they work:

• Scalable manufacturing;
• High stability;
• Non-immunogenic;
• Cost-efficient.

Key applications

• Folate: Targets FR-ɑ in ovarian/lung cancers; pairs with PLGA nanoparticles for oxaliplatin delivery.
• Galactose: Binds ASGPR on hepatocytes for liver-focused therapy (e.g., hepatitis drugs).

Where to use:

When straightforward conjugation, high manufacturability, or compatibility with diverse vehicles (such as liposomes and polymers) is critical.

Carbohydrates

What they are:

Sugar-based molecules (e.g., hyaluronic acid, mannose, galactose) that interact with glycan-binding receptors.

Why they work:

• Biocompatible and naturally occurring (low toxicity);
• Multivalent binding capability enhances target avidity;
• Stable in biological fluids and easy to conjugate to vehicles.

Key applications

• Mannose: Engages CD206 on macrophages in inflammatory bowel disease (IBD).
• Hyaluronic acid: targets CD44 on inflamed colon cells for IBD therapy.

Where to use:

When targeting glycan receptors, biocompatibility, or modulating immune cell activity is required.

How to pick the right ligand (simple checklist):

• Target expression: high in diseased cells, low in healthy cells.
• Internalization: binding should trigger uptake when needed.
• Stability: ligand survives circulation and processing.
• Manufacturability: robust, scalable conjugation and QC.

Table 2 Types of ligands in targeted delivery.

Delivery Vehicles Used with Ligands (Application-Oriented Format)

Different carriers support different payloads, sizes, and biological behaviors. Table 3 lists the main carriers used with ligands in targeted delivery. The vehicle should be selected based on the ligand's inherent properties and the desired therapeutic goals.

Table 3 Delivery Vehicles Used with Ligands.

For detailed platform selection and custom builds, see Module Delivery Systems.

Disease-Area Applications (From Concept to Preclinical Proof)

Ligand-based targeted delivery has advanced from theoretical concepts to robust preclinical validation across key disease areas, including oncology, neurology, infectious disease, inflammation, regenerative medicine, and ex vivo applications.

Oncology

Oncology relies on ligands that bind receptors overexpressed on tumor cells or vasculature. Key ligands used in this area are:

• Folate ligand: it targets folate receptors (FR) on ovarian, breast, and colorectal cancer cells—folate-conjugated polymeric nanoparticles (e.g., PLGA) deliver chemotherapeutics like oxaliplatin, enhancing tumor cell apoptosis while reducing off-target toxicity.
• RGD peptides: they bind αvβ3 integrins on tumor vasculature, guiding liposomes loaded with paclitaxel to solid tumors and improving deep tumor penetration.
• Anti-HER2 antibodies: they target HER2 receptors on breast cancer cells; when conjugated to cytotoxic payloads (as antibody-drug conjugates), they boost intracellular drug accumulation, inhibiting tumor growth in preclinical models.
• Aptamers targeting nucleolin (a receptor on lung and breast cancer cells): they deliver siRNA to silence oncogenes, suppressing tumor proliferation.

Neurology (BBB-Penetrant Delivery)

Neurology focuses on ligands that cross the blood-brain barrier (BBB) and target CNS-specific receptors. Key ligands used in this area are:

• Transferrin: it binds to transferrin receptors (TfR) on BBB endothelial cells—transferrin-modified magnetic nanoparticles deliver paclitaxel to glioma cells, overcoming BBB limitations.
• Angiopep-2: it engages low-density lipoprotein receptor-related protein 1 (LRP1) on BBB cells, enabling liposomes loaded with siRNA to reach glioblastoma cells.
• Anti-CD133 antibodies: they target CD133 receptors on glioblastoma stem cells, delivering photosensitizers to eliminate these therapy-resistant cells in 3D preclinical cultures, addressing CNS tumor recurrence.

Infectious Disease and Inflammation

These area uses ligands to target immune cells or inflamed tissues. Key ligands used in these areas are:

• Hyaluronic acid: as it binds CD44 receptors on inflamed colon epithelial cells, hyaluronic acid-conjugated liposomes can deliver dexamethasone to murine colitis models, reducing intestinal inflammation.
• Mannose: it can target CD206 receptors on macrophages, guiding nanoparticles loaded with antimicrobial agents to intracellular pathogens (e.g., bacteria in macrophages), thus enhancing pathogen clearance.
• Folate ligand: it can also be used to target folate receptors on activated inflammatory macrophages, delivering anti-inflammatory drugs to sites of inflammation (e.g., rheumatoid arthritis) without systemic side effects.

Regenerative Medicine and Ex Vivo Applications

In these areas, ligands direct therapeutic agents or stem cells to damaged tissues. Key ligands used in these areas are:

• RGD peptides: RGD-modified nanoparticles deliver bone morphogenetic protein (BMP) to fracture sites by binding to the αvβ3 integrins on bone progenitor cells, thereby accelerating osteogenesis in rat models.
• Transferrin: transferrin-conjugated gene vectors can transfect MSCs with growth factor genes ex vivo, improving MSC-mediated tissue repair when transplanted.
• Aptamers targeting cardiac-specific receptors (e.g., c-kit): they can guide stem cells homing to damaged myocardium, boosting cardiac regeneration in preclinical models of heart injury.

Designing Effective Ligands: The Shortlist That De-Risks Projects

To de-risk early decisions, work through this design checklist:

Target expression and selectivity

• Verify differential expression in disease vs. healthy tissue;
• Consider single-cell datasets and heterogeneity.

Internalization and trafficking

• Prefer targets that internalize on binding and route to compartments where payloads remain active.

Affinity and avidity

• Aim for K_D in the low nM range;
• Adjust multivalency to bolster functional avidity without steric penalties.

Ligand size and density

• Balance steric hindrance with multivalent binding;
• Test different surface densities on carriers.

Immunogenicity and stability

• Use humanized antibodies, modified aptamers, or non-immunogenic peptides;
• Stabilize with PEGylation or lipid tails as needed.

Conjugation chemistry

• Use site-specific and stable linkers;
• For payload release, consider pH-sensitive, enzyme-cleavable, or reduction-cleavable linkers.

Manufacturability (CMC)

• Favor reproducible synthesis and scalable purification;
• Bake in QC assays early to avoid re-engineering later.

At Creative Biolabs: We provide end-to-end solutions tailored to advance ligand-based targeted delivery projects, from early-stage design to preclinical validation, with a focus on de-risking development and accelerating translational progress.

How Creative Biolabs Accelerates Ligand-Targeted Programs

Discovery & Design

• Target landscaping and ligand shortlisting
• Phage display, SELEX, rational, and AI-guided screening
• Affinity maturation and specificity engineering

Build & Conjugation

• Antibody/peptide/aptamer production and QC
• Site-specific conjugation; cleavable/stable linkers
• Vehicle selection and multivalent presentation

Characterization

• Binding, internalization, and competitive assays
• Particle analytics: DLS, TEM, LC-MS, ligand density quantification
• Stability, sterility, and stress-testing

In Vitro & In Vivo Validation

• Uptake/trafficking in relevant cell systems
• Biodistribution and PK in disease-appropriate models
• Efficacy and tolerability studies with translational endpoints

Explore our platform capabilities here:

Module Delivery Systems

Targeted Delivery Solutions

Related Services You May Be Interested in

FAQs

Conclusion

Ligand-targeted delivery has moved from concept to repeatable, scalable practice. The right pairing of ligand + target + vehicle + chemistry consistently improves on-target exposure, functional activity, and developmental flexibility. With thoughtful design rules, rigorous validation, and CMC-minded builds, teams can move faster and de-risk translation.

Ready to design, build, and validate your ligand-targeted system?

Partner with Creative Biolabs for custom ligand discovery, conjugation chemistry, vehicle engineering, and preclinical validation—all under one roof. Start a project with our experts today:

Talk to our targeted delivery experts | See related module delivery systems we provide

References

1. Chaubey, P., Momin, M. & Sawarkar, S. "Significance of Ligand-Anchored Polymers for Drug Targeting in the Treatment of Colonic Disorders." Front. Pharmacol. 10, 1628 (2020). https://www.frontiersin.org/article/10.3389/fphar.2019.01628/full.
2. Gierlich, P. et al. "Ligand-Targeted Delivery of Photosensitizers for Cancer Treatment." Molecules 25, 5317 (2020). https://www.mdpi.com/1420-3049/25/22/5317.
3. Yan, S., Na, J., Liu, X. & Wu, P. "Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy." Pharmaceutics 16, 248 (2024). https://www.mdpi.com/1999-4923/16/2/248. Distributed under Open Access license CC BY 4.0, without modification.
4. Bajracharya, R. et al. "Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems." Drug Delivery 29, 1959–1970 (2022). https://www.tandfonline.com/doi/full/10.1080/10717544.2022.2089296.